Letter to the Editor: First detection of a Mycobacterium tuberculosis XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023

References

1. Friesen I, Dreyer V, Klingmüller A, Zuber S, Hoffmann AM, Suárez I, et al. First detection of a Mycobacterium tuberculosis XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023. Euro Surveill. 2024;29(28):2400420.  https://doi.org/10.2807/1560-7917.ES.2024.29.28.2400420  PMID: 38994601 
2. World Health Organization (WHO). WHO announces updated critical concentrations for susceptibility testing to rifampicin. Geneva: WHO; 2021. Available from: https://www.who.int/news/item/05-02-2021-who-announces-updated-critical-concentrations-for-susceptibility-testing-to-rifampicin
3. Beckert P, Sanchez-Padilla E, Merker M, Dreyer V, Kohl TA, Utpatel C, et al. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era. Genome Med. 2020;12(1):104.  https://doi.org/10.1186/s13073-020-00793-8  PMID: 33239092 
4. Ushtanit A, Mikhailova Y, Lyubimova A, Makarova M, Safonova S, Filippov A, et al. Genetic profile of linezolid-resistant M. tuberculosis clinical strains from Moscow. Antibiotics (Basel). 2021;10(10):1243.  https://doi.org/10.3390/antibiotics10101243  PMID: 34680823 
5. Bakuła Z, Marczak M, Bluszcz A, Proboszcz M, Kościuch J, Krenke R, et al. Phylogenetic relationships of Mycobacterium tuberculosis isolates in Poland: The emergence of Beijing genotype among multidrug-resistant cases. Front Cell Infect Microbiol. 2023;13:1161905.  https://doi.org/10.3389/fcimb.2023.1161905  PMID: 37009494 
6. World Health Organization (WHO). WHO strengthens tuberculosis control in Ukraine using high-quality diagnostic methods. Geneva: WHO; 2023. Available from: https://www.who.int/azerbaijan/news/item/08-09-2023-who-strengthens-tuberculosis-control-in-ukraine-using-high-quality-diagnostic-methods